Matinas BioPharma Holdings (MTNB) Liabilities and Shareholders Equity (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 51.19% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $34.2 million (down 50.87% YoY), while the FY2025 annual figure was $7.2 million, down 42.98% from the prior year.
• Liabilities and Shareholders Equity declined to $5.9 million in Q1 2026 per MTNB's latest filing, from $7.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $55.8 million in Q1 2022 and bottomed at $5.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $26.5 million across 5 years, with a median of $24.4 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 22.9% — and 2025, when it tumbled 53.11%.
• Matinas BioPharma Holdings' Liabilities and Shareholders Equity stood at $44.8 million in 2022, then tumbled by 43.99% to $25.1 million in 2023, then plunged by 49.65% to $12.6 million in 2024, then plunged by 42.98% to $7.2 million in 2025, then fell by 18.51% to $5.9 million in 2026.
• Business Quant data shows MTNB's Liabilities and Shareholders Equity at $5.9 million in Q1 2026, $7.2 million in Q4 2025, and $9.7 million in Q3 2025.